For Muscular Dystrophy Awareness Month 2026, one of our trustees, Chloe Docker, reflects on scientific progress, the power of early intervention, and why progress is possible when we keep pushing forward together.
The science is catching up: Reflections on progress for Muscular Dystrophy Awareness Month
If you had asked me years ago what the landscape of muscle wasting research would look like today, I honestly wouldn’t have believed you.
As someone who lives with a muscle wasting condition and serves as a trustee for Muscular Dystrophy UK, September – Muscular Dystrophy Awareness Month – always brings a mix of deep reflection and momentum. I often look back at where we started compared to where we are right now.
For decades, the conversation around neuromuscular conditions was almost entirely focused on management and care. Treatment was a distant hope.
Today, that narrative is shifting fundamentally. Science is moving faster than ever.
From hope to reality
We have officially transitioned into an era of actionable medicine. Across various muscle-wasting conditions, we now have 10 approved, life-changing therapies.
Having access to approved treatments is a milestone many of us once wondered if we would ever witness. It represents years of relentless clinical trials, grassroots advocacy, research funding, and the bravery of patients participating in studies worldwide.
The power of early intervention
Alongside treatments, our ability to diagnose conditions before irreversible damage occurs is evolving.
Earlier this year, Scotland launched its spinal muscular atrophy (SMA) newborn screening evaluation program. Just recently, the program identified its first baby with SMA at five days old. Because of that blood spot test, the child was able to begin pre-symptomatic treatment – fundamentally altering their trajectory and giving them the best possible chance at a healthy future.
The momentum continues across the UK. Following tireless campaigning by patient groups, clinicians, and partners across the sector, screening for SMA is rolling out in England. This ensures thousands more families will gain access to that same critical head start.
Seeing early diagnosis work in real time proves that this isn’t just theoretical science – it is actively saving lives right now.
The ripple effect: Why every win matters for everyone
I am acutely aware that we are not there yet for every condition.
Living with or caring for someone with a form of muscular dystrophy that does not yet have an approved treatment is incredibly tough. It can be bittersweet to watch breakthroughs happen in one area while waiting for your own.
However, working on the governance side of this sector has taught me a crucial truth: scientific progress does not happen in isolation.
Every breakthrough creates a powerful ripple effect:
1. Unlocking Pathways: Proving that gene therapies or disease-modifying treatments work in one condition establishes the clinical and regulatory blueprints for others.
2. Infrastructure & Delivery: Establishing screening programs and specialised delivery care within the NHS builds the exact infrastructure required to roll out future treatments faster.
3. Investable Confidence: Success attracts research investment, accelerating trials and pipeline developments across the entire neuromuscular landscape.
A win for SMA, Duchenne, or any single condition brings us closer to answers for all muscle wasting conditions.
We still have a long way to go. We need to expand newborn screening across every nation in the UK, shorten diagnostic odysseys, and ensure equitable access to innovative drugs for every single individual living with a muscle wasting condition.
But this month, I want to take a moment to celebrate how far we’ve come. We are closer than we have ever been.
To the researchers, clinicians, donors, fellow campaigners, and patients who make this progress possible – thank you. Let’s keep pushing forward together.
Find out more about Muscular Dystrophy Awareness month and how you can get involved.
